NASDAQ:TOCA - Tocagen Stock Price, Forecast & News

Tocagen trades on the NASDAQ under the ticker symbol "TOCA."

Tocagen Inc (NASDAQ:TOCA) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.68) by $0.10. The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.01 million. Tocagen had a negative return on equity of 182.15% and a negative net margin of 201,488.91%. View Tocagen's Earnings History.

Tocagen is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Tocagen.

9 brokerages have issued 12-month target prices for Tocagen's shares. Their forecasts range from $1.00 to $28.00. On average, they anticipate Tocagen's share price to reach $8.22 in the next year. This suggests a possible upside of 332.6% from the stock's current price. View Analyst Price Targets for Tocagen.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tocagen in the last year. There are currently 9 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tocagen.

News coverage about TOCA stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Tocagen earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Tocagen.

Tocagen saw a decrease in short interest in January. As of January 15th, there was short interest totalling 2,020,000 shares, a decrease of 14.4% from the December 31st total of 2,360,000 shares. Based on an average trading volume of 533,200 shares, the short-interest ratio is currently 3.8 days. Currently, 9.2% of the shares of the company are sold short. View Tocagen's Current Options Chain.

Some companies that are related to Tocagen include AVEO Pharmaceuticals (AVEO), Catalyst Biosciences (CBIO), Oncolytics Biotech (ONCY), Infinity Pharmaceuticals (INFI), Neos Therapeutics (NEOS), Elite Pharmaceuticals (ELTP), Stealth BioTherapeutics (MITO), Onconova Therapeutics (ONTX), Eyenovia (EYEN), Trevena (TRVN), Chembio Diagnostics (CEMI), Soligenix (SNGX), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX) and Catabasis Pharmaceuticals (CATB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tocagen investors own include Selecta Biosciences (SELB), Nabriva Therapeutics (NBRV), Agile Therapeutics (AGRX), Catalyst Pharmaceuticals (CPRX), vTv Therapeutics (VTVT), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Marinus Pharmaceuticals (MRNS) and SCYNEXIS (SCYX).

(TOCA) raised $80 million in an IPO on Thursday, April 13th 2017. The company issued 7,300,000 shares at $10.00-$12.00 per share. Leerink Partners, Evercore ISI and Stifel acted as the underwriters for the IPO.

Tocagen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (2.24%), Geode Capital Management LLC (1.38%), Acadian Asset Management LLC (0.90%) and Goldman Sachs Group Inc. (0.20%). Company insiders that own Tocagen stock include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Institutional Ownership Trends for Tocagen.

TOCA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp and Acadian Asset Management LLC. View Insider Buying and Selling for Tocagen.

TOCA stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Goldman Sachs Group Inc.. Company insiders that have bought Tocagen stock in the last two years include Faheem Hasnain, Harry E Gruber and Martin J Duvall. View Insider Buying and Selling for Tocagen.

Shares of TOCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TOCA stock can currently be purchased for approximately $1.90.

Tocagen has a market capitalization of $45.41 million and generates $18.04 million in revenue each year. The company earns $-48,960,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Tocagen employs 77 workers across the globe.View Additional Information About Tocagen.

The official website for Tocagen is http://www.tocagen.com/.

Tocagen's mailing address is 4242 CAMPUS POINT COURT SUITE 500, SAN DIEGO CA, 92121. The company can be reached via phone at 858-412-8400 or via email at [email protected]